FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a compound having type 2 somatostatin receptor (SSTR2) receptor antagonist, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for inhibiting type 2 somatostatin receptor activity, a method for inhibiting somatostatin type 2 receptor activity, a method for preventing or treating hypoglycaemia, a method of treating diabetes, using the compound or a salt thereof for inhibiting type 2 somatostatin receptor activity, use of the compound or a salt thereof for preparing a drug for inhibiting somatostatin type 2 receptor activity, using the compound or a salt thereof for preventing or treating hypoglycaemia, using the compound or a salt thereof for preparing a medicament for preventing or treating hypoglycemia, using the compound or a salt thereof for treating diabetes, use of the compound or a salt thereof for preparing a medicament for treating diabetes.
EFFECT: invention extends the range of agents having somatostatin receptor type 2 antagonist activity.
59 cl, 9 dwg, 6 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| TREATING CONDITIONS ASSOCIATED WITH HYPERINSULINEMIA | 2015 |
|
RU2722179C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| ARYLPIPERAZINES, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2220967C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
| PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
| NEW BICYCLIC PYRAZOLE DERIVATIVES | 2018 |
|
RU2781426C2 |
| ACIDYLATED HETEROARYLCONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICAL AGENTS | 2003 |
|
RU2338743C2 |
| CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
